The loan will go towards developing treatments for several cancers and neurological diseases. It supports the Stockholm-based company's research in areas such as radiotherapy and radiosurgery, and also goes towards the software for the treatments.
“The financing gives us greater flexibility to execute our long-term strategy and continue to invest in innovations that improve treatment outcomes, streamline operations and provide a better patient experience,” says Elekta's CFO Klara Eiritz in a press release.
The majority of the work will be carried out in Sweden and the Netherlands. The EIB loan will cover up to half of the investments.
What do you think?